CN101405293B - 天冬氨酰基蛋白酶抑制剂基于赖氨酸的前体药物及其制备方法 - Google Patents

天冬氨酰基蛋白酶抑制剂基于赖氨酸的前体药物及其制备方法 Download PDF

Info

Publication number
CN101405293B
CN101405293B CN200680051907.4A CN200680051907A CN101405293B CN 101405293 B CN101405293 B CN 101405293B CN 200680051907 A CN200680051907 A CN 200680051907A CN 101405293 B CN101405293 B CN 101405293B
Authority
CN
China
Prior art keywords
compound
group
formula
carbon atoms
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200680051907.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN101405293A (zh
Inventor
G·米洛特
S·布兰乔德
B·R·斯特瑞克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taimed Biologics Inc
Original Assignee
Ambrilia Biopharma Inc
Taimed Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambrilia Biopharma Inc, Taimed Biologics Inc filed Critical Ambrilia Biopharma Inc
Publication of CN101405293A publication Critical patent/CN101405293A/zh
Application granted granted Critical
Publication of CN101405293B publication Critical patent/CN101405293B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN200680051907.4A 2005-11-30 2006-11-30 天冬氨酰基蛋白酶抑制剂基于赖氨酸的前体药物及其制备方法 Expired - Fee Related CN101405293B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74064205P 2005-11-30 2005-11-30
US60/740,642 2005-11-30
PCT/CA2006/001963 WO2007062526A1 (en) 2005-11-30 2006-11-30 Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation

Publications (2)

Publication Number Publication Date
CN101405293A CN101405293A (zh) 2009-04-08
CN101405293B true CN101405293B (zh) 2013-03-13

Family

ID=38091843

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200680051907.4A Expired - Fee Related CN101405293B (zh) 2005-11-30 2006-11-30 天冬氨酰基蛋白酶抑制剂基于赖氨酸的前体药物及其制备方法

Country Status (8)

Country Link
US (2) US8227450B2 (enExample)
EP (1) EP1971615B1 (enExample)
JP (1) JP2009517412A (enExample)
CN (1) CN101405293B (enExample)
AU (1) AU2006319716B2 (enExample)
CA (1) CA2632095A1 (enExample)
ES (1) ES2452718T3 (enExample)
WO (1) WO2007062526A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10149030A1 (de) 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
US7388008B2 (en) 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
JP2009517412A (ja) 2005-11-30 2009-04-30 アンブリリア バイオファーマ インコーポレイテッド アスパルチルプロテアーゼ阻害物質のリジンベースのプロドラッグ及びその調製方法
AU2007287353A1 (en) * 2006-07-17 2008-02-28 Ambrilia Biopharma Inc. Method for improving pharmacokinetics
AU2007337830A1 (en) 2006-09-21 2008-07-03 Ambrilia Biopharma Inc. Benzenesulfonamide derivatives as HIV protease inhibitors
WO2009148600A2 (en) * 2008-06-06 2009-12-10 Concert Pharmaceuticals, Inc. Deuterated lysine-based compounds
CA2762582A1 (en) 2009-05-27 2010-12-02 Merck Sharp & Dohme Corp. Hiv protease inhibitors
WO2012055031A1 (en) 2010-10-28 2012-05-03 Merck Canada Inc. Hiv protease inhibitors
EP2771332B1 (en) 2011-10-26 2016-06-29 Merck Canada Inc. Thiophen and thiazol sulfonamid derivatives as HIV protease inhibitors for the treatment of AIDS
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US10369129B2 (en) 2016-05-31 2019-08-06 Taimed Biologics, Inc. Long acting pharmaceutical composition of protease inhibitor
WO2017209732A1 (en) * 2016-05-31 2017-12-07 Taimed Biologics, Inc. A long acting pharmaceutical composition of protease inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632816B1 (en) * 2002-12-23 2003-10-14 Pharmacor Inc. Aromatic derivatives as HIV aspartyl protease inhibitors

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013861A (en) 1985-02-28 1991-05-07 E. R. Squibb & Sons, Inc. Ester substituted aminoalkanoylureido amino and imino acid and ester compounds
JPH06501950A (ja) 1990-10-11 1994-03-03 ベーリンガー　インゲルハイム　コマンディトゲゼルシャフト 環状ペプチド、その調製法およびその薬理組成物としての使用
US5614522A (en) 1990-11-19 1997-03-25 G.D. Searle & Co. Retroviral protease inhibitors
EP0532466A3 (en) 1991-09-12 1993-06-16 Ciba-Geigy Ag Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use
EP0656888B1 (en) 1992-08-25 1998-01-07 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US6022994A (en) 1992-08-25 2000-02-08 G. D. Searle &. Co. Succinoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US5463104A (en) 1992-08-25 1995-10-31 G. D. Searle & Co. Succinoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
JPH06321950A (ja) 1993-05-14 1994-11-22 Takeda Chem Ind Ltd 水溶性ランカシジン誘導体
WO1995006998A1 (en) 1993-08-31 1995-03-09 Stanley Kugell Telephone billing method
WO1995024385A1 (en) 1994-03-07 1995-09-14 Vertex Pharmaceuticals Incorporated Sulphonamide derivatives as aspartyl protease inhibitors
US5527829A (en) 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
ES2303337T3 (es) 1995-01-20 2008-08-01 G.D. Searle Llc Inhibidores de la proteasa retroviral de bis-hidroxietilamino sulfonamida.
US5985870A (en) 1995-03-10 1999-11-16 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
US5776718A (en) 1995-03-24 1998-07-07 Arris Pharmaceutical Corporation Reversible protease inhibitors
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
JP2000501111A (ja) 1996-01-26 2000-02-02 バーテックス ファーマシューティカルズ インコーポレイテッド アスパルチルプロテアーゼインヒビター
AU720615B2 (en) 1997-01-17 2000-06-08 Pharmacia & Upjohn Company Bis-sulfonomides hydroxamic acids as MMP inhibitors
PT877019E (pt) 1997-05-09 2002-05-31 Hoechst Ag Acidos diaminocarboxilicos substituidos
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
EE200000386A (et) * 1997-12-24 2001-12-17 Vertex Pharmaceuticals Incorporated Aspartüülproteaasi inhibiitorite eelravimid
US5986102A (en) 1998-04-29 1999-11-16 Pharmacopeia, Inc. Hydroxypropylamide peptidomimetics as inhibitors of aspartyl proteases
ATE311391T1 (de) 1999-02-12 2005-12-15 Vertex Pharma Aspartyl-protease-inhibitoren
AR031520A1 (es) 1999-06-11 2003-09-24 Vertex Pharma Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion
US6656968B1 (en) * 1999-06-16 2003-12-02 Temple University - Of The Commonwealth System Of Higher Education (Z)-styryl acetoxyphenyl sulfides as cyclooxygenase inhibitors
US6455587B1 (en) * 2000-03-15 2002-09-24 Pharmacor Inc. Amino acid derivatives as HIV aspartyl protease inhibitors
US6506786B2 (en) 2001-02-13 2003-01-14 Pharmacor Inc. HIV protease inhibitors based on amino acid derivatives
EP1480941B1 (en) 2002-03-04 2011-01-26 Ambrilia Biopharma Inc. Urea derivatives as hiv aspartyl protease inhibitors
CA2374362C (en) 2002-03-04 2008-01-22 Brent Richard Stranix Urea derivatives as hiv aspartyl protease inhibitors
PL376900A1 (pl) 2002-12-16 2006-01-09 Boehringer Ingelheim International Gmbh Zastosowanie kombinacji zawierającej nienukleozydowy inhibitor odwrotnej transkryptazy (NNRTI) i inhibitor cytochromu P450, taki jak inhibitor proteazy
AU2004312284B2 (en) 2004-01-08 2010-08-05 Medivir Ab Non-nucleotide reverse transcriptase inhibitors
US7388008B2 (en) 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
ATE417823T1 (de) 2004-08-02 2009-01-15 Ambrilia Biopharma Inc Verbindungen auf lysinbasis
EP1877091B1 (en) 2005-04-27 2015-03-25 TaiMed Biologics, Inc. Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors
JP2009517412A (ja) 2005-11-30 2009-04-30 アンブリリア バイオファーマ インコーポレイテッド アスパルチルプロテアーゼ阻害物質のリジンベースのプロドラッグ及びその調製方法
AU2007287353A1 (en) 2006-07-17 2008-02-28 Ambrilia Biopharma Inc. Method for improving pharmacokinetics
AU2007337830A1 (en) 2006-09-21 2008-07-03 Ambrilia Biopharma Inc. Benzenesulfonamide derivatives as HIV protease inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632816B1 (en) * 2002-12-23 2003-10-14 Pharmacor Inc. Aromatic derivatives as HIV aspartyl protease inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
李宗韦.STN检索报告.《STN检索报告》.2010, *

Also Published As

Publication number Publication date
JP2009517412A (ja) 2009-04-30
US20100130765A1 (en) 2010-05-27
CN101405293A (zh) 2009-04-08
US20090253926A1 (en) 2009-10-08
AU2006319716A1 (en) 2007-06-07
EP1971615B1 (en) 2014-01-01
EP1971615A4 (en) 2011-06-22
HK1124861A1 (en) 2009-07-24
ES2452718T3 (es) 2014-04-02
US8227450B2 (en) 2012-07-24
AU2006319716B2 (en) 2012-02-02
WO2007062526A1 (en) 2007-06-07
EP1971615A1 (en) 2008-09-24
US8580995B2 (en) 2013-11-12
WO2007062526A8 (en) 2007-08-30
CA2632095A1 (en) 2007-06-07

Similar Documents

Publication Publication Date Title
US8580995B2 (en) Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation
JP3437553B2 (ja) （３ｓ）テトラヒドロ−３−フラニル（１ｓ，２ｒ）−３−［［（４−アミノフェニル）スルホニル］（イソブチル）アミノ］−１−ベンジル−２−（ホスホノオキシ）プロピルカルバミン酸カルシウム
US20080269172A1 (en) Lysine based compounds
CN103951643A (zh) 用作hiv整合酶抑制剂的化合物
DE60221508T2 (de) Aminosäurederivate als hiv-protease-inhibitoren
EP2258681A2 (en) Aromatic Derivatives as HIV Aspartyl Protease Inhibitors
JP2010502569A (ja) 薬物動態学の改善方法
ES2575871T3 (es) Composiciones farmacéuticas que comprende un compuesto a base de lisina y un agente antiviral o antirretroviral VIH
HK1124861B (en) Lysme-based prodrugs of aspartyl protease inhibitors and processes for their preparation
RU2379312C2 (ru) Соединения на основе лизина, фармацевтическая композиция, содержащая эти соединения, применение указанных соединений для лечения или профилактики вич инфекции
CN102093411A (zh) 基于赖氨酸的化合物
JPH11269135A (ja) アミノカルボン酸誘導体およびそれを有効成分とする薬剤
HK1105406B (en) Lysine based compounds
ZA200607352B (en) Lysine based compounds
HK1099235A1 (en) Phosphonate analogs of hiv integrase inhibitor compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: TAIMED BIOLOGICS

Free format text: FORMER OWNER: AMBRILIA BIOPHARMA INC.

Effective date: 20130128

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; TO: TAIWAN, CHINA

TA01 Transfer of patent application right

Effective date of registration: 20130128

Address after: Taiwan, China

Applicant after: Taimed Biologics, Inc.

Address before: Quebec

Applicant before: Ambrilia Biopharma Inc.

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130313

Termination date: 20201130

CF01 Termination of patent right due to non-payment of annual fee